因此,PAD4 通过转录调控负向调节不同巨噬细胞亚群的 MHC II 类表达。 作者验证了 PAD4 与巨噬细胞中 MHC II 类相关信号之间的反向关系。对上述单细胞 RNA 测序数据进行的基因组富集分析(Gene set enriched analysis,GSEA)显示,小鼠 Padi4 高的巨噬细胞表现出多种上调通路,包括肽基精氨酸修饰(GO: 0018195)、...
首先,为了尽量排除已知抗原激活免疫应答的影响,研究团队特地选择了免疫原性很低,免疫检查点抑制剂治疗基本无效的一个恶性肉瘤细胞系,给这些癌细胞插上MHC I类和II类新抗原来展开实验。 由于已被确认的MHC II类限定分子新抗原很少,研究团...
1144MHC II neoantigen vaccines improve antitumor immunity and response to immune checkpoint inhibitor in cold tumordoi:10.1136/jitc-2023-SITC2023.1144Background Cold tumor is one of the most refractory solid tumors and experience dismal response to immune checkpoint blockade (ICBs). Most therapeutic ...
NOG-dKO(NOG-MHC I/II-2 KO)小鼠是由日本中央实验动物研究所(CIEM)的Mamoru Ito博士培育而成。Mamoru Ito博士实验室利用CRISPR技术在NOG小鼠基础上敲除B2m和Ab1基因,培育出的双基因敲除模型。 * CIEM已将NOG-dKO在日本地区的名称更新为NOG-ΔMHC (NOG-Iab KO, B2m KO2),但在中国地区维通利华仍沿用NOG-dKO名...
Atherosclerosis is accompanied by a CD4 T cell response to apolipoprotein B (APOB). Major histocompatibility complex class II (MHC-II) tetramers can be used to isolate antigen-specific CD4 T cells by flow sorting. Here, we produce, validate and use an MHC-II tetramer, DRB1*07:01 AP...
(at protein level), and myeloma cells. Research studies have shown that BST2 also functions as an inhibitor of retrovirus release from human cells whose activity is antagonized by the HIV-1 accessory protein, Vpu. While BST2 causes retention of virions on cell surfaces or endocytosis into BST...
MHCII类反式激活蛋白调控肿瘤细胞HLA分子的表达
Interestingly, some tumors that express MHC class II also express inhibitors for the MHC class II antigen presentation process. Most notably is the inhibitor for HLA-DM, HLA-DO, in B cell leukemia. Whether this again reflects a differentiation difference (HLA-DO is best expressed in immature B...
This is of relevance not only in a plethora of intractable autoimmune conditions, but also in the context of checkpoint inhibitor therapy, where autoimmune related adverse events are the main cause of treatment cessation. Conversely, it also opens an entirely novel avenue of possibilities, such as...
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) +/- anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies J. Immunother. Cancer, 10 (2022) Google Scholar [29] C.D. Zahm, J.E. Moseman, L.E. Delmastro G.M. D, PD-1 and LAG-3 blockade improve...